Influence study of non-platinum cytotoxic drugs on polymerase chain reaction

The tumor is a cellular process, whose essence is the change of the genetic information and regulatory processes in the cell. Consequently, occurs to the uncontrolled multiplication of cells. Cytostatics, especially anthracycline antibiotics are currently widely used for example in the treatment of breast cancer or prostate cancer, which are nowadays the most frequent cancers. The influence of non-platinum cytotoxic drug doxorubicin on polymerase chain reaction can be studied using fluorescent labelling of amplicons. Due to numerous side-effects of doxorubicin, it is important to know its mechanism of influence on living cells. Polymerase chain reaction can serve as a suitable model of replication in living cells.

Figure 1: doxorubicin intercalation into DNA double helix

1. Kennedy S., Oswald N., PCR Troubleshooting and Optimization: The Essential Guide, Caister Academic Press, 2011.
2. Henegariu O., Heerema N. A., Dlouhy S. R., Vance G. H., Vogt P. H.: Biotechniques, 23, 504 (1997).
3. Raclavsky V.: (2003).
4. Sherstyuk V. V., Shevchenko A. I., Zakian S. M.: Chromosoma, 123, 183 (2014).
5. Perou C. M., Sorlie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Rees C. A., Pollack J. R., Ross D. T., Johnsen H., Akslen L. A., Fluge O., Pergamenschikov A., Williams C., Zhu S. X., Lonning P. E., Borresen-Dale A. L., Brown P. O., Botstein D.: Nature, 406, 747 (2000).
6. Kovalova L., McArdell C. S., Hollender J.: Journal of Chromatography A, 1216, 1100 (2009).
7. Negreira N., Lopez de Alda M., Barcelo D.: The Science of the total environment, 482-483, 389 (2014).
8. Jehn U., Heinemann V.: Anticancer Research, 11, 705 (1991).
9. Basar E. Z., Corapcioglu F., Babaoglu K., Anik Y., Daglioz G. G., Dedeoglu R.: Pediatric Hematology and Oncology, 31, 237 (2014).
10. Raj S., Franco V. I., Lipshultz S. E.: Current treatment options in cardiovascular medicine, 16, 315 (2014).
11. Bains O. S., Szeitz A., Lubieniecka J. M., Cragg G. E., Grigliatti T. A., Riggs K. W., Reid R. E.: Journal of Pharmacology and Experimental Therapeutics, 347, 375 (2013).
12. Tang S., Yin Q., Zhang Z., Gu W., Chen L., Yu H., Huang Y., Chen X., Xu M., Li Y.: Biomaterials, 35, 6047 (2014).
13. Wang G., Edwards H., Caldwell J. T., Buck S. A., Qing W. Y., Taub J. W., Ge Y. B., Wang Z. H.: Plos One, 8, (2013).
14. Varshosaz J., Hassanzadeh F., Aliabadi H. S., Nayebsadrian M., Banitalebi M., Rostami M.: Biomed Research International, (2014).
15. Burley K., Allford S.: British Journal of Haematology, 165, 70 (2014).
16. Fairey A. S., Daneshmand S., Quinn D., Dorff T., Dorin R., Lieskovsky G., Schuckman A., Cai J., Miranda G., Skinner E. C.: Urologic Oncology-Seminars and Original Investigations, 31, 1737 (2013).
17. Silverman H. I.: New England Journal of Medicine, 333, 257 (1995).
18. Shoji T., Takatori E., Kaido Y., Omi H., Yokoyama Y., Mizunuma H., Kaiho M., Otsuki T., Takano T., Yaegashi N., Nishiyama H., Fujimori K., Sugiyama T.: Cancer Chemotherapy and Pharmacology, 73, 895 (2014).
19. Box V. G. S.: Journal of Molecular Graphics & Modelling, 26, 14 (2007).
20. Agudelo D., Bourassa P., Berube G., Tajmir-Riahi H. A.: International Journal of Biological Macromolecules, 66, 144 (2014).
21. Kato M., Nakayama M., Agata M., Yoshida K.: Tumor Biology, 34, 723 (2013).
22. Elford H. L., Cardounel A. J., Zweier J., Henry J., Sumpter R., Oakley O., Gallicchio V.: Proceedings of the American Association for Cancer Research Annual Meeting, 47, 502 (2006).
23. Taatjes D. J., Fenick D. J., Gaudiano G., Koch T. H.: Current Pharmaceutical Design, 4, 203 (1998).
24. Post G. C., Barthel B. L., Burkhart D. J., Hagadorn J. R., Koch T. H.: Journal of Medicinal Chemistry, 48, 7648 (2005).
25. Popenoe E. A., Schmaeler M. A.: Archives of Biochemistry and Biophysics, 196, 109 (1979).
26. Sartiano G. P., Lynch W. E., Bullington W. D.: Journal of Antibiotics, 32, 1038 (1979).

PDF